Loading...
•
Dec 31, 2023
Teva Q4 2023 Earnings Report
Reported growth in Q4 and full year 2023, driven by innovative brands and strategic collaborations.
Key Takeaways
Teva Pharmaceutical Industries Ltd. reported a strong Q4 2023, with revenues of $4.5 billion, a 15% increase compared to Q4 2022. GAAP diluted earnings per share were $0.41, and non-GAAP diluted EPS was $1.00. The company's growth was driven by an upfront payment from an anti-TL1A asset collaboration, sale of product rights in Europe, and higher revenues from generic products and AUSTEDO.
Revenues increased by 15% to $4.5 billion, driven by upfront payments and innovative products.
GAAP diluted EPS reached $0.41, while non-GAAP diluted EPS was $1.00.
Gross profit margin improved to 54.2%, due to upfront payments and product mix.
The company's 'Pivot to Growth' strategy is progressing, focusing on growth engines and innovation.
Teva
Teva
Teva Revenue by Segment
Teva Revenue by Geographic Location
Revenue by Segment
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comInternational Markets Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comEurope Revenue
CapyFin.comInternational Markets Revenue
CapyFin.com Forward Guidance
Teva provided its 2024 outlook, including revenue expectations of $15.7-$16.3 billion and non-GAAP diluted EPS of $2.20-$2.50.
Positive Outlook
- Revenues of $15.7 – $16.3 billion
- AUSTEDO revenues of ~$1,500 million
- AJOVY revenues of ~$500 million
- UZEDY revenues of ~$80 million
- COPAXONE revenues of ~$400 million
Challenges Ahead
- Operating Income of $4.0 – $4.5
- Adjusted EBITDA of $4.5 – $5.0
- Finance Expenses of ~$1,000 million
- Tax Rate of 14% – 17%
- Free Cash Flow of $1.7 - $2.0
Revenue & Expenses
Visualization of income flow from segment revenue to net income